Kristina Jankovic: 12-year follow-up of the C9741 trial
Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared a post on X about a recent paper by Otto Metzger Filho et al. published in the Journal of Clinical Oncology:
“C9741 trial 12-year FU in Journal of Clinical Oncology.
Dose-dense ChT = sustained benefit in N+
- +23% DFS (HR 0.77)
- +20% OS (HR 0.80)
- Low SET2,3 biomarker = biggest benefit in ER+
- No tumor burden, molecular subtype, menopausal status ≠ predictive.”
“Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer”
Authors: Otto Metzger Filho, Karla Ballman, Jordan Campbell, Larry Norton, Fraser Symmans et al.
More posts featuring Kristina Jankovic.
Kristina Jankovic, MD, is a Medical Oncology Resident at the University Clinical Center Niš, where she works at the Oncology Clinic. Her primary interests include breast cancer, innovative cancer therapies, oncofertility, and hereditary cancers. She is a member of ESMO, ASCO, and the European School of Oncology (ESO).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023